Ammar Al-Zoubi

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

Andrzej Jakubowiak, Dominik Dytfeld, Kent A. Griffith et al. · Blood · 2012 · 434 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase II Trial of Combination Therapy With Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Myeloma

Andrzej Jakubowiak, Tara Kendall, Ammar Al-Zoubi et al. · Journal of Clinical Oncology · 2009 · 76 citations

Medicine, Hematology, Pharmacotherapy +16

Aggressive Chronic Lymphocytic Leukemia with Elevated Genomic Complexity Is Associated with Multiple Gene Defects in the Response to DNA Double-Strand Breaks

Peter Ouillette, Samuel Fossum, Brian Parkin et al. · Clinical Cancer Research · 2010 · 74 citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +17

Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM)

Andrzej Jakubowiak, Dominik Dytfeld, Sundar Jagannath et al. · Blood · 2011 · 24 citations

Medicine, Oncology, Pharmacotherapy +12

High Rate of Complete and near Complete Responses (CR/nCR) after Initial Therapy with Bortezomib (Velcade®), Doxil®, and Dexamethasone (VDD) Is Further Increased after Autologous Stem Cell Transplantation (ASCT).

Andrzej Jakubowiak, Ammar Al-Zoubi, Tara Kendall et al. · Blood · 2006 · 14 citations

Medicine, Pharmacology, Pharmacotherapy +10